{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:59:31Z","timestamp":1791323971776,"version":"4.3.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40262-020-00976-x","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T01:02:32Z","timestamp":1617066152000},"page":"1171-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects"],"prefix":"10.1007","volume":"60","author":[{"given":"Andreas B.","family":"Jordy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Albayaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Breitschaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Houshmand-\u00d8regaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Easwaran","family":"Manigandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine A.","family":"B\u00e6kdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"issue":"4","key":"976_CR1","first-page":"178","volume":"10","author":"KL Tran","year":"2017","unstructured":"Tran KL, Park YI, Pandya S, Muliyil NJ, Jensen BD, Huynh K, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178\u201388.","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"976_CR2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbol JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"976_CR3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, Sargin M, Karsbol JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"976_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258\u201366.","journal-title":"Diabetes Care"},{"issue":"5","key":"976_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, Piletic M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"976_CR6","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN\u00a05): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"key":"976_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","volume":"104","author":"L Jensen","year":"2017","unstructured":"Jensen L, Helleberg H, Roffel A, van Lier JJ, Bj\u00f8rnsdottir I, Pedersen PJ, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31\u201341.","journal-title":"Eur J Pharm Sci"},{"issue":"18","key":"976_CR8","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370\u201380.","journal-title":"J Med Chem"},{"issue":"5","key":"976_CR9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcph.443","volume":"55","author":"C Kapitza","year":"2015","unstructured":"Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel. J Clin Pharmacol. 2015;55(5):497\u2013504.","journal-title":"J Clin Pharmacol"},{"key":"976_CR10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/dc15-2479","volume":"39","author":"M Nauck","year":"2016","unstructured":"Nauck M, Petrie J, Sesti G, Mannucci E, Courr\u00e8ges J, Lindegaard M, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231\u201341.","journal-title":"Diabetes Care"},{"issue":"6","key":"976_CR11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","volume":"58","author":"C Granhall","year":"2019","unstructured":"Granhall C, Donsmark M, Blicher TM, Golor G, S\u00f8ndergaard FL, Thomsen M, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58(6):781\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"467","key":"976_CR12","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"ST Buckley","year":"2018","unstructured":"Buckley ST, B\u00e6kdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-R\u00f8nne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.","journal-title":"Sci Transl Med."},{"issue":"5","key":"976_CR13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bcp.12557","volume":"79","author":"MA Karsdal","year":"2015","unstructured":"Karsdal MA, Riis BJ, Mehta N, Stern W, Arbit E, Christiansen C, et al. Lessons learned from the clinical development of oral peptides. Br J Clin Pharmacol. 2015;79(5):720\u201332.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"976_CR14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1185\/03007990902905724","volume":"25","author":"AZ Fu","year":"2009","unstructured":"Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin. 2009;25(6):1413\u201320.","journal-title":"Curr Med Res Opin"},{"issue":"15","key":"976_CR15","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460\u201370.","journal-title":"JAMA"},{"issue":"9","key":"976_CR16","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial comparing the efficacy and safety of oral semaglutide monotherapy with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332.","journal-title":"Diabetes Care"},{"issue":"15","key":"976_CR17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER\u00a03 randomized clinical trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA"},{"issue":"10192","key":"976_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39\u201350.","journal-title":"Lancet"},{"issue":"12","key":"976_CR19","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","volume":"57","author":"C Granhall","year":"2018","unstructured":"Granhall C, Sondergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57(12):1571\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"976_CR20","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/jcph.1131","volume":"58","author":"TA Baekdal","year":"2018","unstructured":"Baekdal TA, Thomsen M, Kupcova V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314\u201323.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"976_CR21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1345\/aph.1Q583","volume":"46","author":"KM Hurren","year":"2012","unstructured":"Hurren KM, Pinelli NR. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother. 2012;46(5):710\u20137.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"976_CR22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","volume":"20","author":"JB Hjerpsted","year":"2018","unstructured":"Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"976_CR23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","volume":"58","author":"TA B\u00e6kdal","year":"2019","unstructured":"B\u00e6kdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clin Pharmacokinet. 2019;58(9):1193\u2013203.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"976_CR24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0010-7824(96)00136-9","volume":"54","author":"K Fotherby","year":"1996","unstructured":"Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. 1996;54(2):59\u201369.","journal-title":"Contraception"},{"issue":"3","key":"976_CR25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","volume":"75","author":"O von Richter","year":"2004","unstructured":"von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004;75(3):172\u201383.","journal-title":"Clin Pharmacol Ther"},{"key":"976_CR26","doi-asserted-by":"crossref","first-page":"23763","DOI":"10.1038\/srep23763","volume":"6","author":"Y-Q Liu","year":"2016","unstructured":"Liu Y-Q, Yuan L-M, Gao Z-Z, Xiao Y-S, Sun H-Y, Yu L-S, et al. Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities. Sci Rep. 2016;6:23763.","journal-title":"Sci Rep"},{"issue":"2","key":"976_CR27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","volume":"46","author":"H Zhang","year":"2007","unstructured":"Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46(2):133\u201357.","journal-title":"Clin Pharmacokinet"},{"key":"976_CR28","unstructured":"Data on File, Novo Nordisk, 2015."},{"issue":"5","key":"976_CR29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","volume":"18","author":"LL Boles","year":"1990","unstructured":"Boles LL, Schoenwald RD. Furosemide (Frusemide) A pharmacokinetic\/pharmacodynamic review (part I). Clin Pharmacokinet. 1990;18(5):381\u2013408.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"976_CR30","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25(11):2822\u201335.","journal-title":"Clin Ther"},{"issue":"8","key":"976_CR31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3109\/00498254.2011.562566","volume":"41","author":"GT Generaux","year":"2011","unstructured":"Generaux GT, Bonomo FM, Johnson M, Mahar Doan KM. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica. 2011;41(8):639\u201351.","journal-title":"Xenobiotica"},{"key":"976_CR32","unstructured":"Data on File, Novo Nordisk, 2015."},{"key":"976_CR33","volume-title":"Clinical drug interaction studies\u2014study design, data analysis, and clinical implications. Guidance for industry","author":"Food and Drug Administration","year":"2017","unstructured":"Food and Drug Administration. Clinical drug interaction studies\u2014study design, data analysis, and clinical implications. Guidance for industry. Rockville: FDA; 2017."},{"key":"976_CR34","unstructured":"Novo Nordisk A\/S. A trial investigating the influence of oral semaglutide on pharmacokinetics of ethinylestradiol and levonorgestrel in an oral contraceptive combination drug in healthy postmenopausal females [ClinicalTrials.gov identifier NCT02845219]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov. Accessed 10 Dec 2020."},{"key":"976_CR35","unstructured":"Novo Nordisk A\/S. A trial investigating the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects [ClinicalTrials.gov identifier NCT03010475]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov. Accessed 10 Dec 2020."},{"key":"976_CR36","volume-title":"Declaration of Helsinki. Recommendations guiding medical doctors in biomedical research involving human subjects. 48th WMA General Assembly","author":"World Medical Association","year":"1996","unstructured":"World Medical Association. Declaration of Helsinki. Recommendations guiding medical doctors in biomedical research involving human subjects. 48th WMA General Assembly. Somerset West, Republic of South Africa; 1996."},{"key":"976_CR37","unstructured":"European Medicines Agency. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1), Step 4; 1996. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e6-r1-guideline-good-clinical-practice_en.pdf. Accessed 10 Dec 2020."},{"key":"976_CR38","unstructured":"Food and Drug Administration. Foreign clinical studies not conducted under an IND. FDA Code of Federal Regulations, 21 CFR 312.120; 2014."},{"key":"976_CR39","volume-title":"Drug interaction studies \u2013 study design, data analysis, implications for dosing, and labeling recommendations. Draft Guidance","author":"Food and Drug Administration","year":"2012","unstructured":"Food and Drug Administration. Drug interaction studies \u2013 study design, data analysis, implications for dosing, and labeling recommendations. Draft Guidance. Silver Spring: Center for Drug Evaluation and Research, Food and Drug Administration; 2012."},{"key":"976_CR40","volume-title":"Guideline on the investigation of drug interactions","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. London: European Medicines Agency; 2012."},{"issue":"6","key":"976_CR41","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2125.2007.03035.x","volume":"64","author":"L Haegeli","year":"2007","unstructured":"Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Kr\u00e4henb\u00fchl S, et al. Sublingual administration of furosemide: new application of an old drug. Br J Clin Pharmacol. 2007;64(6):804\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"976_CR42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF00556898","volume":"27","author":"A Grahnen","year":"1984","unstructured":"Grahnen A, Hammarlund M, Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol. 1984;27(5):595\u2013602.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"976_CR43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2042098612439884","volume":"3","author":"M Hu","year":"2012","unstructured":"Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf. 2012;3(3):133\u201344.","journal-title":"Ther Adv Drug Saf"},{"issue":"6","key":"976_CR44","first-page":"631","volume":"32","author":"S Ramkumar","year":"2016","unstructured":"Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631\u20139.","journal-title":"Acta Cardiol Sin"},{"issue":"4","key":"976_CR45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0009-9236(02)17633-8","volume":"73","author":"KJ Cooper","year":"2003","unstructured":"Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini W. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2003;73(4):322\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"976_CR46","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/dom.13358","volume":"20","author":"KCC Petri","year":"2018","unstructured":"Petri KCC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Diabetes Obes Metab. 2018;20(9):2238\u201345.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"976_CR47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Holm Hels O. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"976_CR48","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"976_CR49","first-page":"2272","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg S\u00d8, et al. PIONEER 2 Investigators. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"PIONEER 2 Investigators. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial"},{"issue":"12","key":"976_CR50","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E. PIONEER 8 Investigators. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262\u201371.","journal-title":"Diabetes Care"},{"issue":"3","key":"976_CR51","first-page":"366","volume":"96","author":"J Symons","year":"2000","unstructured":"Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators. Obstet Gynecol. 2000;96(3):366\u201372.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"976_CR52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/humupd\/dmm001","volume":"13","author":"J Collins","year":"2007","unstructured":"Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update. 2007;13(5):421\u201331.","journal-title":"Hum Reprod Update"},{"issue":"6","key":"976_CR53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0010-7824(80)90086-4","volume":"22","author":"J Dickerson","year":"1980","unstructured":"Dickerson J, Bressler R, Christian CD. Liver function tests and low-dose estrogen oral contraceptives. Contraception. 1980;22(6):597\u2013603.","journal-title":"Contraception"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00976-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00976-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00976-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T10:13:16Z","timestamp":1698142396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00976-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00976-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"30 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Both trials were sponsored by Novo Nordisk A\/S, S\u00f8borg, Denmark.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tine A. B\u00e6kdal, Erik Christiansen, Azadeh Houshmand-\u00d8regaard, Easwaran Manigandan and Andreas B. Jordy are Novo Nordisk employees. Tine A. B\u00e6kdal, Thomas W. Anderson, Erik Christiansen, Azadeh Houshmand-\u00d8regaard and Easwaran Manigandan own stocks or shares in Novo Nordisk. Thomas W. Anderson is a former employee of Novo Nordisk.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human subjects were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual subjects included in these trials.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}